Evolving Role of Biomarkers in Prostate Cancer : Episode 6
Opinion
Video
Risk Stratification in Prostate Cancer Patients
Medical oncologists explore risk stratification strategies for newly diagnosed patients with prostate cancer, emphasizing the significant role of the Gleason score in diagnosis and prognosis.
Video Player is loading.
Video content above is prompted by the following question:
- How do you approach risk stratification in prostate cancer patients, specifically in those newly diagnosed? (Brian Richardson, MD)
- Do you rely on the Gleason score, specific biomarkers, or a combination?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Fitting Oral ADT Options Into the Prostate Cancer Treatment Plans
The Current Landscape of ADT in Prostate Cancer
Christine Ibilibor, MD, highlights study of racial differences in abiraterone use
Laura Davis, MD, on persistent poverty and early onset prostate cancer
Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
Ruben Olivares, MD, discusses HIFU and remote prostate cancer care
Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
Post-RP incontinence: Low procedure rates examined
Data link incontinence severity to post-radical prostatectomy care
Related Content
